Immunovant, Inc.
IMVTNext catalyst
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Get an email about IMVT's next catalysts
Track Immunovant (IMVT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 1 past
IMVT Earnings Report
EPS Est: $-0.73 | FQ end Sep/2026 | Call: bmo
IMVT-1402 Phase 2 Est. Readout
Primary completion for IMVT-1402 trial (NCT06980805) in Subacute Cutaneous Lupus Erythematosus
SourceIMVT-1402 Phase 2 Est. Readout
Primary completion for IMVT-1402 trial (NCT06754462) in Rheumatoid Arthritis
SourceMarket Overview
Stock performance and key metrics
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab
Thyroid Eye Disease
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Chronic Inflammatory Demyelinating Polyneuropathy
RVT-1401
Myasthenia Gravis
IMVT-1401 (batoclimab)
Graves Disease
Imeroprubart
Chronic Inflammatory Demyelinating Polyneuropathy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMVT-1402 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Batoclimab | Phase 3 | Thyroid Eye Disease | - | - |
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
RVT-1401 | Phase 2 | Myasthenia Gravis | - | - |
IMVT-1401 (batoclimab) | Phase 2 | Graves Disease | - | - |
Imeroprubart | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Frequently asked questions
What is in Immunovant, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Immunovant, Inc.'s (IMVT) pipeline across Phase 3, Phase 2. Its lead program is IMVT-1402 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immunovant, Inc.'s next FDA catalyst?→
Immunovant, Inc.'s (IMVT) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMVT biotech catalysts?→
Add IMVT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunovant, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.